Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.
Numerous studies have tested the association between TP53 mutations in ovarian cancer and prognosis but these have been consistently confounded by limitations in study design, methodology, and/or heterogeneity in the sample cohort. High-grade serous (HGS) carcinoma is the most clinically important h...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2010
|
| _version_ | 1797078228607696896 |
|---|---|
| author | Ahmed, A Etemadmoghadam, D Temple, J Lynch, A Riad, M Sharma, R Stewart, C Fereday, S Caldas, C Defazio, A Bowtell, D Brenton, J |
| author_facet | Ahmed, A Etemadmoghadam, D Temple, J Lynch, A Riad, M Sharma, R Stewart, C Fereday, S Caldas, C Defazio, A Bowtell, D Brenton, J |
| author_sort | Ahmed, A |
| collection | OXFORD |
| description | Numerous studies have tested the association between TP53 mutations in ovarian cancer and prognosis but these have been consistently confounded by limitations in study design, methodology, and/or heterogeneity in the sample cohort. High-grade serous (HGS) carcinoma is the most clinically important histological subtype of ovarian cancer. As these tumours may arise from the ovary, Fallopian tube or peritoneum, they are collectively referred to as high-grade pelvic serous carcinoma (HGPSC). To identify the true prevalence of TP53 mutations in HGPSC, we sequenced exons 2-11 and intron-exon boundaries in tumour DNA from 145 patients. HGPSC cases were defined as having histological grade 2 or 3 and FIGO stage III or IV. Surprisingly, pathogenic TP53 mutations were identified in 96.7% (n = 119/123) of HGPSC cases. Molecular and pathological review of mutation-negative cases showed evidence of p53 dysfunction associated with copy number gain of MDM2 or MDM4, or indicated the exclusion of samples as being low-grade serous tumours or carcinoma of uncertain primary site. Overall, p53 dysfunction rate approached 100% of confirmed HGPSCs. No association between TP53 mutation and progression-free or overall survival was found. From this first comprehensive mapping of TP53 mutation rate in a homogeneous group of HGPSC patients, we conclude that mutant TP53 is a driver mutation in the pathogenesis of HGPSC cancers. Because TP53 mutation is almost invariably present in HGPSC, it is not of substantial prognostic or predictive significance. |
| first_indexed | 2024-03-07T00:29:04Z |
| format | Journal article |
| id | oxford-uuid:7f24babb-fa91-40c9-a6bf-ab7afd29a0ac |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:29:04Z |
| publishDate | 2010 |
| record_format | dspace |
| spelling | oxford-uuid:7f24babb-fa91-40c9-a6bf-ab7afd29a0ac2022-03-26T21:14:53ZDriver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7f24babb-fa91-40c9-a6bf-ab7afd29a0acEnglishSymplectic Elements at Oxford2010Ahmed, AEtemadmoghadam, DTemple, JLynch, ARiad, MSharma, RStewart, CFereday, SCaldas, CDefazio, ABowtell, DBrenton, JNumerous studies have tested the association between TP53 mutations in ovarian cancer and prognosis but these have been consistently confounded by limitations in study design, methodology, and/or heterogeneity in the sample cohort. High-grade serous (HGS) carcinoma is the most clinically important histological subtype of ovarian cancer. As these tumours may arise from the ovary, Fallopian tube or peritoneum, they are collectively referred to as high-grade pelvic serous carcinoma (HGPSC). To identify the true prevalence of TP53 mutations in HGPSC, we sequenced exons 2-11 and intron-exon boundaries in tumour DNA from 145 patients. HGPSC cases were defined as having histological grade 2 or 3 and FIGO stage III or IV. Surprisingly, pathogenic TP53 mutations were identified in 96.7% (n = 119/123) of HGPSC cases. Molecular and pathological review of mutation-negative cases showed evidence of p53 dysfunction associated with copy number gain of MDM2 or MDM4, or indicated the exclusion of samples as being low-grade serous tumours or carcinoma of uncertain primary site. Overall, p53 dysfunction rate approached 100% of confirmed HGPSCs. No association between TP53 mutation and progression-free or overall survival was found. From this first comprehensive mapping of TP53 mutation rate in a homogeneous group of HGPSC patients, we conclude that mutant TP53 is a driver mutation in the pathogenesis of HGPSC cancers. Because TP53 mutation is almost invariably present in HGPSC, it is not of substantial prognostic or predictive significance. |
| spellingShingle | Ahmed, A Etemadmoghadam, D Temple, J Lynch, A Riad, M Sharma, R Stewart, C Fereday, S Caldas, C Defazio, A Bowtell, D Brenton, J Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. |
| title | Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. |
| title_full | Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. |
| title_fullStr | Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. |
| title_full_unstemmed | Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. |
| title_short | Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. |
| title_sort | driver mutations in tp53 are ubiquitous in high grade serous carcinoma of the ovary |
| work_keys_str_mv | AT ahmeda drivermutationsintp53areubiquitousinhighgradeserouscarcinomaoftheovary AT etemadmoghadamd drivermutationsintp53areubiquitousinhighgradeserouscarcinomaoftheovary AT templej drivermutationsintp53areubiquitousinhighgradeserouscarcinomaoftheovary AT lyncha drivermutationsintp53areubiquitousinhighgradeserouscarcinomaoftheovary AT riadm drivermutationsintp53areubiquitousinhighgradeserouscarcinomaoftheovary AT sharmar drivermutationsintp53areubiquitousinhighgradeserouscarcinomaoftheovary AT stewartc drivermutationsintp53areubiquitousinhighgradeserouscarcinomaoftheovary AT feredays drivermutationsintp53areubiquitousinhighgradeserouscarcinomaoftheovary AT caldasc drivermutationsintp53areubiquitousinhighgradeserouscarcinomaoftheovary AT defazioa drivermutationsintp53areubiquitousinhighgradeserouscarcinomaoftheovary AT bowtelld drivermutationsintp53areubiquitousinhighgradeserouscarcinomaoftheovary AT brentonj drivermutationsintp53areubiquitousinhighgradeserouscarcinomaoftheovary |